Equity Profile

SRRK

Scholar Rock Holding Corporation

Health CareBiotechnology$6.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Scholar Rock Holding Corporation is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its unique approach to protein regulation, which could have significant implications for patient care.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of -$0.83, slightly missing expectations. The stock reacted negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Scholar Rock's upcoming earnings are mixed, given the company's recent performance and lack of analyst estimates. Investors are keen to see if the company can turn around its earnings trajectory.

Bull Case

The optimistic view hinges on potential positive developments in ongoing clinical trials or new partnerships that could lead to increased revenue and improved EPS.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide a clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch this as it could indicate future revenue potential and the company's ability to meet development milestones.

Will there be any guidance on revenue expectations for the next quarter?

Clear revenue guidance is crucial for investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could significantly enhance the company's market position and investor sentiment.

Supporting Evidence

Historically, the stock has shown resilience after misses, indicating potential for recovery.

Options pricing suggests a larger move than what has been realized in the past, indicating heightened expectations.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and significantly impact the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to deliver on its promises and improve its financial performance.

Bull Confirmed If

A positive update on clinical trial results or a new partnership announcement could signal a strong future outlook.

Bear Confirmed If

Continued misses on EPS and lack of revenue guidance would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant potential move in either direction, reflecting uncertainty around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.4% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations, history suggests a potential stock increase of around 1.15% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 1.15%, reflecting ongoing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and any new data.
2Management's outlook on revenue expectations for the next quarter.
3Any announcements regarding partnerships or collaborations.
4Insights into cost management strategies and their impact on EPS.
5Discussion of market opportunities and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of -$0.83, slightly missing expectations. The stock reacted negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on potential positive developments in ongoing clinical trials or new partnerships that could lead to increased revenue and improved EPS.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide a clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch this as it could indicate future revenue potential and the company's ability to meet development milestones.

Will there be any guidance on revenue expectations for the next quarter?

Clear revenue guidance is crucial for investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for positive clinical trial results, which could significantly enhance the company's market position and investor sentiment.

Supporting Evidence

Historically, the stock has shown resilience after misses, indicating potential for recovery.

Options pricing suggests a larger move than what has been realized in the past, indicating heightened expectations.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and significantly impact the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to deliver on its promises and improve its financial performance.

Bull Confirmed If

A positive update on clinical trial results or a new partnership announcement could signal a strong future outlook.

Bear Confirmed If

Continued misses on EPS and lack of revenue guidance would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant potential move in either direction, reflecting uncertainty around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats expectations, history suggests a potential stock increase of around 1.15% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 1.15%, reflecting ongoing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and any new data.
2Management's outlook on revenue expectations for the next quarter.
3Any announcements regarding partnerships or collaborations.
4Insights into cost management strategies and their impact on EPS.
5Discussion of market opportunities and competitive landscape.